Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 16/20 | 0.72 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.72 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071325 | 0.94 | CHRNB2 (0.69) | CHRNB2CHRNA4TGFBR1ACVR1 | |
| SCHEMBL5657098 | 0.87 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL6353136 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1 | |
| SCHEMBL5658776 | 0.85 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5657410 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1 | |
| SCHEMBL3060282 | 0.84 | CHRNB2 (0.89) | CHRNB2CHRNA4 | |
| SCHEMBL5655721 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA1CHRNA7TGFBR1 | |
| SCHEMBL5658618 | 0.83 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5658712 | 0.79 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5656700 | 0.79 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4312456-B2 | — | — | 2009-08-12 | — | — | JP | claimed |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2007-11-15 | — | — | US | claimed |
| US-7282494-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | claimed |
| EP-1757600-A2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NeuroSearch A/S (DK) | 2007-02-28 | — | — | EP | claimed |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | DANPET AB (SE) | 2006-05-11 | — | — | US | claimed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | claimed |
| JP-2004510813-A | — | — | 2004-04-08 | — | — | JP | claimed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | claimed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | claimed |
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2010-10-21 | — | — | US | disclosed |
| US-7307087-B2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH A/S (DK) | 2007-12-11 | — | — | US | disclosed |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2007-11-15 | — | — | US | disclosed |
| US-7282494-B2 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| EP-1757600-A2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NeuroSearch A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | DANPET AB (SE) | 2006-05-11 | — | — | US | disclosed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | disclosed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
| EP-1175416-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000064885-A1 | HETEROARYL DIAZACYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | TAAR5, CHRNA5, CHRNA4 | CHRNB2 15/4885CHRNA4 3/4885CHRNA1 6/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | CHRNB2 15/4885CHRNA4 3/4885CHRNA1 6/4885 |
| US-20060100192-A1 | Heteroaryl diazacycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA3 | CHRNB2 10/4885CHRNA4 9/4885CHRNA1 6/4885 |
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | CHRNA10, CHRNA2, CHRNA7 | CHRNB2 14/4885CHRNA4 5/4885CHRNA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.